Evidence map›Paper›PMID 26341514›Full record

ArticleHepatology international2016

Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus.

Jian-Jun Luo, Zi-Han Zhang, Qing-Xin Liu, Wen Zhang, Jian-Hua Wang, Zhi-Ping Yan

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02971345 (Endovascular Brachytherapy Combined With Stent Placement and Transcatheter Arterial Chemoembolization), which is not on this map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02971345 phase3unknown statusnot on this mapstarted 2017, after this paper: background citation

Endovascular Brachytherapy Combined With Stent Placement and Transcatheter Arterial Chemoembolization (TACE) for Treatment of HCC With Main Portal Vein Tumor Thrombus Versus TACE Alone: a Prospective Randomized Controlled Multicentre Trial

TypeinterventionalSponsorShanghai Zhongshan HospitalRan2017 to 2020Enrolled253ConditionsHepatocellular Carcinoma, Portal Vein Tumor ThrombusArmsStent and Iodine-125 seed strand implantation, Stent, Iodine-125 seed, Epirubicin, Ultra-fluid lipiodol
3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Hepatic infarction occurred afterJournal of cancer research and clinical oncology · 2024
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. [Percutaneous biliary stent combined with brachytherapy for malignant obstructive jaundice: a multicenter retrospective controlled study].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jian-Jun LuoDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, 200032, Shanghai, China.
Zi-Han ZhangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, 200032, Shanghai, China.
Qing-Xin LiuDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, 200032, Shanghai, China.
Wen ZhangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, 200032, Shanghai, China.
Jian-Hua WangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, 200032, Shanghai, China.
Zhi-Ping YanDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, 200032, Shanghai, China. yan.zhiping@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

proposeTo evaluate the safety and efficacy of endovascular brachytherapy (EVBT) with iodine-125 ((125)I) seed strand implantation combined with stent placement and transarterial chemoembolization (TACE) to treat hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (MPVTT).

methodsData of 276 consecutive HCC patients with MPVTT treated by stent placement and TACE were analyzed retrospectively. (125)I seed strands were implanted in 182 patients (group A). The remaining 94 patients, who did not receive EVBT, served as control (group B). The overall survival, free of disease progression survival, stent patency period and procedure-related complications were compared between the two groups.

resultsDuring a mean 9.9 ± 9.7 month (range 1.3-62.2 months) follow-up, the median survival time was 9.3 ± 0.9 months (95 % CI 7.6-11.0 months) in group A compared to 4.9 ± 0.5 months (95 % CI 4.0-5.8 months) in group B (p < 0.001). Median free of disease progression survival time in group A and B was 1.8 ± 0.1 months (95 % CI 1.6-2.0 months) and 1.5 ± 0.1 months (95 % CI 1.3-1.7 months), respectively (p < 0.001). Median stent patency period was 9.2 ± 1.1 months (95 % CI 7.0-11.4 months) in group A and 4.8 ± 0.5 months (95 % CI 3.9-5.7 months) in group B, respectively (p < 0.001).

conclusionThese findings suggested that EVBT combined with stent placement and TACE might be a safe and effective palliative treatment option for HCC with main portal vein tumor thrombus.

Indexed as

StentsAdultAgedAged, 80 and overBrachytherapyCarcinoma, HepatocellularChemoembolization, TherapeuticCombined Modality TherapyFemaleHumansIodine RadioisotopesLiver NeoplasmsMaleMiddle AgedPortal VeinRetrospective StudiesIodine RadioisotopesEndovascular brachytherapyHepatocellular carcinomaMain portal veinStent placementTransarterial cheoembolizationTumor thrombus

Identifiers

PMID26341514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.